Cited 7 times in
US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김민정 | - |
dc.contributor.author | 김은경 | - |
dc.contributor.author | 문희정 | - |
dc.date.accessioned | 2017-02-24T03:30:46Z | - |
dc.date.available | 2017-02-24T03:30:46Z | - |
dc.date.issued | 2016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146361 | - |
dc.description.abstract | BACKGROUND: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. METHODS: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K(trans), k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. RESULTS: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥ 20% showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K(trans) values than non-TN cancers (p = 0.048). CONCLUSION: THC obtained from US-DOT and K(trans) obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1~9 | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Biomarkers, Tumor/metabolism | - |
dc.subject.MESH | Breast Neoplasms/diagnostic imaging | - |
dc.subject.MESH | Breast Neoplasms/metabolism* | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Contrast Media/administration & dosage | - |
dc.subject.MESH | Estrogen Receptor alpha/metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hemoglobins/isolation & purification | - |
dc.subject.MESH | Hemoglobins/pharmacokinetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Image Interpretation, Computer-Assisted | - |
dc.subject.MESH | Ki-67 Antigen/metabolism | - |
dc.subject.MESH | Magnetic Resonance Imaging/methods* | - |
dc.subject.MESH | Molecular Imaging/methods | - |
dc.subject.MESH | Neovascularization, Pathologic/diagnostic imaging | - |
dc.subject.MESH | Neovascularization, Pathologic/metabolism | - |
dc.subject.MESH | Neovascularization, Pathologic/pathology | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiography | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism | - |
dc.subject.MESH | Receptors, Progesterone/metabolism | - |
dc.subject.MESH | Tomography, Optical/methods* | - |
dc.title | US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Radiology | - |
dc.contributor.googleauthor | Min Jung Kim | - |
dc.contributor.googleauthor | Min-Ying Su | - |
dc.contributor.googleauthor | Hon J Yu | - |
dc.contributor.googleauthor | Jeon-Hor Chen | - |
dc.contributor.googleauthor | Eun-Kyung Kim | - |
dc.contributor.googleauthor | Hee Jung Moon | - |
dc.contributor.googleauthor | Ji Soo Choi | - |
dc.identifier.doi | 10.1186/s12885-016-2086-7 | - |
dc.contributor.localId | A00473 | - |
dc.contributor.localId | A00801 | - |
dc.contributor.localId | A01397 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.relation.journalsince | 2001~ | - |
dc.identifier.pmid | 26833069 | - |
dc.contributor.alternativeName | Kim, Min Jung | - |
dc.contributor.alternativeName | Kim, Eun Kyung | - |
dc.contributor.alternativeName | Moon, Heui Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Min Jung | - |
dc.contributor.affiliatedAuthor | Kim, Eun-Kyung | - |
dc.contributor.affiliatedAuthor | Moon, Heui Jeong | - |
dc.citation.volume | 16 | - |
dc.citation.number | 50 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.16(50) : 1-9, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 47870 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.